The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
Featured:
Zinaida Peric
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
What do current data tell us regarding the most effective regimen for ECP treatment in steroid-refractory cGvHD?
A
B
C
D
Video series
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).
Zinaida Perić, University of Rijeka, Rijeka, HR, shared her thoughts on patient eligibility, treatment optimization, and follow-up after treatment with ECP for cGvHD. She also discussed a case report of a patient with steroid-refractory (SR)-cGvHD, plus retrospective (Table 1) and prospective data on the use of ECP in cGvHD. In addition, she shared the Nordic ECP Quality Group treatment guidelines for SR-cGvHD.
Table 1. Retrospective data of ECP in SR-cGvHD*
ECP, extracorporeal photopheresis; SR-cGvHD, steroid-resistant chronic graft-versus-host disease.
*Data from Nygaard et al.1
Figure 1. Treatment guidelines proposed by the Nordic ECP Quality Group*
cGvHD, chronic graft-versus-host disease; CR, complete response; ECP, extracorporeal photopheresis; MR, minimal response; mixR, mixed response; NC, no change; PR, partial response; SR, steroid-refractory.
*Adapted from Lee et al.2
Listen to this presentation as a podcast here:
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
Q&A session
This symposium closed with a panel Q&A session with live audience participation, where our panelists discussed their perspectives on donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops.
Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
